Eye­ing quick ap­proval, Ab­b­Vie of­fers a close-up on their pres­by­opia drug da­ta

Ab­b­Vie picked up some bonus points ear­li­er this year as one of its pipeline adds from the $63 bil­lion Al­ler­gan buy­out hit its top-line marks. And now the re­searchers have pro­duced the de­tailed da­ta on the case they are mak­ing with reg­u­la­tors, with an eye on a ma­jor new mar­ket and a hoped-for ap­proval be­fore New Year’s.

AGN-190584 is aim­ing to be the first easy-on eye­drop for pres­by­opia, a com­mon ail­ment for large num­bers of peo­ple who find it hard­er and hard­er to read things like a watch or cell phone close up. Any­one who’s held a book out at arm’s length in or­der to read it will be very fa­mil­iar with the con­di­tion, if not the ex­act di­ag­no­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER